Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2

BACKGROUND: Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or intolerance to at least one biologic disease-modifying antirheumatic drug (DMARD). METHODS: In this 24...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J, Lertratanakul, Apinya, Anderson, Jaclyn K, Papp, Kim, Van den Bosch, Filip, Tsuji, Shigeyoshi, Dokoupilova, Eva, Keiserman, Mauro, Wang, Xin, Zhong, Sheng, McCaskill, Reva M, Zueger, Patrick, Pangan, Aileen L, Tillett, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892371/
https://www.ncbi.nlm.nih.gov/pubmed/33272960
http://dx.doi.org/10.1136/annrheumdis-2020-218870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892371/
https://www.ncbi.nlm.nih.gov/pubmed/33272960
http://dx.doi.org/10.1136/annrheumdis-2020-218870

Ejemplares similares